Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.

Journal article

Scott EM. et al, (2019), J Immunother Cancer, 7

Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.

Journal article

Scott EM. et al, (2018), Macromol Biosci, 18

Generation of stable packaging and producer cell lines for scalable lentiviral vector production

Conference paper

Dunajova L. et al, (2017), HUMAN GENE THERAPY, 28, A39 - A39

Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.

Journal article

Duffy MR. et al, (2017), Hum Gene Ther, 28, 1033 - 1046

Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.

Journal article

Freedman JD. et al, (2017), EMBO Mol Med, 9, 1067 - 1087

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.

Journal article

Illingworth S. et al, (2017), Mol Ther Oncolytics, 5, 62 - 74

Load More